These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 23690423)
21. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986 [TBL] [Abstract][Full Text] [Related]
22. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028 [TBL] [Abstract][Full Text] [Related]
23. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM; J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353 [TBL] [Abstract][Full Text] [Related]
24. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822 [TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094 [TBL] [Abstract][Full Text] [Related]
26. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. Chau I; Norman AR; Cunningham D; Waters JS; Oates J; Ross PJ J Clin Oncol; 2004 Jun; 22(12):2395-403. PubMed ID: 15197201 [TBL] [Abstract][Full Text] [Related]
27. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600 [TBL] [Abstract][Full Text] [Related]
28. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814 [TBL] [Abstract][Full Text] [Related]
29. Enrollment in clinical trials correlates with improved survival in metastatic melanoma. Seetharamu N; Tu TJ; Christos P; Ott PA; Berman RS; Shapiro RL; Osman I; Pavlick AC Oncology; 2011; 81(5-6):403-9. PubMed ID: 22270052 [TBL] [Abstract][Full Text] [Related]
30. Survival and prognostic factors of stage I-III breast cancer. Laohavinij S; Ruikchuchit K; Maneechavakajorn J J Med Assoc Thai; 2013 Mar; 96 Suppl 3():S23-34. PubMed ID: 23682519 [TBL] [Abstract][Full Text] [Related]
31. Melanoma of unknown primary origin: a population-based study in the Netherlands. de Waal AC; Aben KK; van Rossum MM; Kiemeney LA Eur J Cancer; 2013 Feb; 49(3):676-83. PubMed ID: 23031553 [TBL] [Abstract][Full Text] [Related]
32. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923 [TBL] [Abstract][Full Text] [Related]
33. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. Voit C; Kron M; Rademaker J; Schwürzer-Voit M; Sterry W; Weber L; Ozdemir C; Proebstle T; Keilholz U J Clin Oncol; 2005 Feb; 23(6):1218-27. PubMed ID: 15718319 [TBL] [Abstract][Full Text] [Related]
34. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789 [TBL] [Abstract][Full Text] [Related]
35. Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? A retrospective study of 14 patients with malignant melanoma stage IV. Doerler M; Hyun J; Venten I; Potthoff A; Bartke U; Serova K; Hoextermann S; Altmeyer P; Brockmeyer NH Eur J Med Res; 2007 Oct; 12(10):497-502. PubMed ID: 18024256 [TBL] [Abstract][Full Text] [Related]
36. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer. Haughey BH; Sinha P Laryngoscope; 2012 Sep; 122 Suppl 2():S13-33. PubMed ID: 22926949 [TBL] [Abstract][Full Text] [Related]
37. Sex differences in melanoma survival are not related to mitotic rate of the primary tumor. Joosse A; van der Ploeg AP; Haydu LE; Nijsten TE; de Vries E; Scolyer RA; Eggermont AM; Coebergh JW; Thompson JF Ann Surg Oncol; 2015 May; 22(5):1598-603. PubMed ID: 25408275 [TBL] [Abstract][Full Text] [Related]